# Pyxis Oncology, Inc.: financial statements, quarterly

PYXS · Nasdaq · CIK 1782223 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pyxs.md) · [Financials](/companies/pyxs/financials.md) · [Filings](/companies/pyxs/filings.md) · [Insiders](/companies/pyxs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pyxs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [16.1](/filings/0000950170-25-071996.md) | [0.0 d](/filings/0000950170-25-108906.md) | [0.0 d](/filings/0001193125-25-261696.md) | [0.0 d](/filings/0001193125-26-118532.md) | not reported | [2.8](/filings/0000950170-25-108906.md) | [0.0 d](/filings/0001193125-25-261696.md) | [11.0 d](/filings/0001193125-26-118532.md) | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | [0.5](/filings/0000950170-25-071996.md) | [0.0 d](/filings/0000950170-25-108906.md) | [0.0 d](/filings/0001193125-25-261696.md) | [0.0 d](/filings/0001193125-26-118532.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [14.7](/filings/0000950170-24-124602.md) | [11.6 d](/filings/0000950170-25-040771.md) | [13.0](/filings/0000950170-25-071996.md) | [14.0](/filings/0000950170-25-108906.md) | [17.7](/filings/0001193125-25-261696.md) | [14.0 d](/filings/0001193125-26-118532.md) | [17.0](/filings/0001193125-26-222843.md) | [17.1](/filings/0001193125-26-347913.md) | [17.8](/filings/0001193125-25-261696.md) | [21.7 d](/filings/0001193125-26-118532.md) | [20.0](/filings/0001193125-26-222843.md) | [16.1](/filings/0001193125-26-347913.md) |
| Operating income | $m | [(25.4)](/filings/0000950170-24-124602.md) | [(17.8) d](/filings/0000950170-25-040771.md) | [(5.6)](/filings/0000950170-25-071996.md) | [(20.0)](/filings/0000950170-25-108906.md) | [(23.8)](/filings/0001193125-25-261696.md) | [(40.1) d](/filings/0001193125-26-118532.md) | [(22.9)](/filings/0001193125-26-222843.md) | [(19.8)](/filings/0001193125-26-347913.md) | [(23.5)](/filings/0001193125-25-261696.md) | [(18.3) d](/filings/0001193125-26-118532.md) | [(24.4)](/filings/0001193125-26-222843.md) | [(26.0)](/filings/0001193125-26-347913.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001193125-26-347913.md) | [0.0 d](/filings/0001193125-25-261696.md) | [1.1 d](/filings/0001193125-26-118532.md) | not reported | [0.0](/filings/0001193125-26-347913.md) |
| Net income | $m | [(23.0)](/filings/0000950170-24-124602.md) | [(15.6) d](/filings/0000950170-25-040771.md) | [(3.3)](/filings/0000950170-25-108906.md) | [(17.3)](/filings/0000950170-25-108906.md) | [(21.2)](/filings/0001193125-25-261696.md) | [(35.6) d](/filings/0001193125-26-118532.md) | [(21.2)](/filings/0001193125-26-347913.md) | [(18.4)](/filings/0001193125-26-347913.md) | [(22.0)](/filings/0001193125-25-261696.md) | [(18.1) d](/filings/0001193125-26-118532.md) | [(23.3)](/filings/0001193125-26-347913.md) | [(25.3)](/filings/0001193125-26-347913.md) |
| Diluted EPS | $ per share | [(0.56)](/filings/0000950170-24-124602.md) | not reported | [(0.06)](/filings/0000950170-25-071996.md) | [(0.29)](/filings/0000950170-25-108906.md) | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.35)](/filings/0001193125-26-222843.md) | [(0.30)](/filings/0001193125-26-347913.md) | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.37)](/filings/0001193125-26-222843.md) | [(0.40)](/filings/0001193125-26-347913.md) |
| Basic EPS | $ per share | [(0.56)](/filings/0000950170-24-124602.md) | not reported | [(0.06)](/filings/0000950170-25-071996.md) | [(0.29)](/filings/0000950170-25-108906.md) | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.35)](/filings/0001193125-26-222843.md) | [(0.30)](/filings/0001193125-26-347913.md) | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.37)](/filings/0001193125-26-222843.md) | [(0.40)](/filings/0001193125-26-347913.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.7](/filings/0000950170-24-124602.md) | [9.7](/filings/0000950170-25-040771.md) | [28.0](/filings/0000950170-25-071996.md) | [25.1](/filings/0000950170-25-108906.md) | [12.1](/filings/0001193125-25-261696.md) | [19.5](/filings/0001193125-26-118532.md) | [12.8](/filings/0001193125-26-222843.md) | [10.7](/filings/0001193125-26-347913.md) | [8.9](/filings/0001193125-25-261696.md) | [15.4](/filings/0001193125-26-347913.md) | [5.8](/filings/0001193125-26-222843.md) | [18.9](/filings/0001193125-26-347913.md) |
| Current assets | $m | [139](/filings/0000950170-23-060354.md) | [125](/filings/0000950170-25-040771.md) | [172](/filings/0000950170-24-059099.md) | [161](/filings/0000950170-24-097073.md) | [149](/filings/0000950170-24-124602.md) | [132](/filings/0001193125-26-118532.md) | [112](/filings/0000950170-25-071996.md) | [100.0](/filings/0000950170-25-108906.md) | [83.1](/filings/0001193125-25-261696.md) | [72.1](/filings/0001193125-26-347913.md) | [45.6](/filings/0001193125-26-222843.md) | [36.7](/filings/0001193125-26-347913.md) |
| Total assets | $m | [187](/filings/0000950170-23-060354.md) | [174](/filings/0000950170-25-040771.md) | [220](/filings/0000950170-24-059099.md) | [208](/filings/0000950170-24-097073.md) | [195](/filings/0000950170-24-124602.md) | [157](/filings/0001193125-26-118532.md) | [136](/filings/0000950170-25-071996.md) | [123](/filings/0000950170-25-108906.md) | [106](/filings/0001193125-25-261696.md) | [91.5](/filings/0001193125-26-347913.md) | [64.3](/filings/0001193125-26-222843.md) | [54.9](/filings/0001193125-26-347913.md) |
| Current liabilities | $m | [28.3](/filings/0000950170-23-060354.md) | [25.8](/filings/0000950170-25-040771.md) | [14.1](/filings/0000950170-24-059099.md) | [16.9](/filings/0000950170-24-097073.md) | [20.3](/filings/0000950170-24-124602.md) | [17.7](/filings/0001193125-26-118532.md) | [14.4](/filings/0000950170-25-071996.md) | [17.7](/filings/0000950170-25-108906.md) | [19.4](/filings/0001193125-25-261696.md) | [21.1](/filings/0001193125-26-347913.md) | [16.5](/filings/0001193125-26-222843.md) | [27.5](/filings/0001193125-26-347913.md) |
| Total liabilities | $m | [48.7](/filings/0000950170-23-060354.md) | [48.0](/filings/0000950170-25-040771.md) | [36.1](/filings/0000950170-24-059099.md) | [38.6](/filings/0000950170-24-097073.md) | [41.6](/filings/0000950170-24-124602.md) | [36.4](/filings/0001193125-26-118532.md) | [32.8](/filings/0000950170-25-071996.md) | [35.6](/filings/0000950170-25-108906.md) | [36.8](/filings/0001193125-25-261696.md) | [38.1](/filings/0001193125-26-347913.md) | [33.0](/filings/0001193125-26-222843.md) | [43.5](/filings/0001193125-26-347913.md) |
| Shareholders' equity | $m | [138](/filings/0000950170-24-124602.md) | [126](/filings/0001193125-26-118532.md) | [184](/filings/0000950170-25-108906.md) | [170](/filings/0001193125-25-261696.md) | [154](/filings/0001193125-25-261696.md) | [121](/filings/0001193125-26-347913.md) | [103](/filings/0001193125-26-347913.md) | [87.6](/filings/0001193125-26-347913.md) | [68.8](/filings/0001193125-25-261696.md) | [53.4](/filings/0001193125-26-347913.md) | [31.3](/filings/0001193125-26-347913.md) | [11.4](/filings/0001193125-26-347913.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.6) d](/filings/0000950170-24-124602.md) | [(15.3) d](/filings/0000950170-25-040771.md) | [(20.7)](/filings/0000950170-25-071996.md) | [(3.0) d](/filings/0000950170-25-108906.md) | [(14.7) d](/filings/0001193125-25-261696.md) | [(19.3) d](/filings/0001193125-26-118532.md) | [(22.5)](/filings/0001193125-26-222843.md) | [(17.3) d](/filings/0001193125-26-347913.md) | [(13.3) d](/filings/0001193125-25-261696.md) | [(10.4) d](/filings/0001193125-26-118532.md) | [(26.0)](/filings/0001193125-26-222843.md) | [(18.2) d](/filings/0001193125-26-347913.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-124602.md) | [0.0 d](/filings/0000950170-25-040771.md) | [0.2](/filings/0000950170-25-071996.md) | [0.0 d](/filings/0000950170-25-108906.md) | [0.0 d](/filings/0001193125-25-261696.md) | [0.0 d](/filings/0001193125-26-118532.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-118532.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.6](/filings/0000950170-23-060354.md) | [35.4](/filings/0000950170-24-059099.md) | [38.4](/filings/0000950170-24-097073.md) | [41.3](/filings/0000950170-24-124602.md) | [51.3](/filings/0000950170-25-071996.md) | [60.5](/filings/0000950170-25-108906.md) | [60.7](/filings/0001193125-25-261696.md) | [61.0](/filings/0001193125-26-222843.md) | [61.9](/filings/0001193125-26-347913.md) | [62.6](/filings/0001193125-25-261696.md) | [63.5](/filings/0001193125-26-222843.md) | [64.0](/filings/0001193125-26-347913.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 83,408,050 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347913.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.